Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dermaliq Therapeutics

Request full access

Innovative dermatology solutions enhancing hair growth and wound healing with advanced topical therapies

Heidelberg, GermanyFounded 2021Biotech & Life Sciences

About Dermaliq Therapeutics

Dermaliq Therapeutics is a pioneering company in the dermatology sector, focusing on the development of advanced topical therapies for hair growth and wound healing. The company serves a diverse clientele, including individuals seeking medical aesthetics, self-pay prescription products, and over-the-counter (OTC) solutions. Operating in the healthcare and pharmaceutical markets, Dermaliq leverages its unique hyliQ™ platform technology to deliver multiple active ingredients directly into the follicle and skin, enhancing efficacy and safety. The business model revolves around continuous clinical development and regulatory approval of its products, generating revenue through product sales and potentially licensing its technology. Dermaliq's flagship products, DLQ01 and DLQ03, have shown significant promise in clinical trials, demonstrating superior efficacy in hair regrowth and accelerated wound healing, respectively. The company is poised to become a leader in next-generation dermatological treatments, driven by a commitment to innovation and quality.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
58.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2022 $15M $60M 3E Bioventures · Beijing Weiying Technology ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Dermaliq Therapeutics website traffic

Latest recorded traffic for Dermaliq Therapeutics is 1.8K monthly website visits, up 1025% over the last three months. Dermaliq Therapeutics's team declined 37.5% over the past year.

Latest monthly visits1.8K 3-month web change+1025% 1-year team growth-37.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
New American TherapeuticsA privately held, specialty pharmaceutical company that acquires, markets and develops products in select therapeutic areas Parsippany-Troy Hills, United States Operational — $53M —
Steel TherapeuticsFocused on increasing access to life-changing therapies with a track record of efficacy from compounding pharmacies Iowa City, United States Operational
CellmAbsCellmabs is focused on researching and developing innovative biopharmaceuticals for the treatment of cancer Óbidos, Portugal Acquired
ImmuneOnco BiopharmaDedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells Huangpu, China Operational
AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases London, United Kingdom Operational
UppertonPharmaceutical CDMO for oral and nasal dosage forms Nottingham, United Kingdom Operational
Caris Life SciencesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics Irving, United States Operational
Leap TherapeuticsA biopharmaceutical company in the clinical stage, acquiring and advancing innovative therapeutics at the forefront of cancer research Cambridge, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Dermaliq Therapeutics in the Heidelberg ecosystem

Live from Dealroom

The Dermaliq Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • 3E Bioventures
  • Beijing Weiying Technology
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany66.7%
🇺🇸 United States33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Dermaliq Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dermaliq Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.